Zoetis Inc. (NYSE:ZTS)
Zoetis Inc. (NYSE:ZTS) represented a move of -0.32 percent or $1.07 per share and closed its previous day trading session at $93.57. 1.92 Million Shares were traded in the last trading session with an Average Volume of 2.29 Million Shares. The stock currently has a Market Capitalization of 45.1 Billion.
Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
The stock traded between $70.20 and $96.57 over 1-Year time period showing its price to sales ratio of 7.88. Zoetis Inc. (NYSE:ZTS) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $2.35 and 200-Day Simple Moving Average of $7.48. Its Price to Free Cash Flow is 36.43 and Price to Book of 21.31.
Analyst’s recommended the stock as 1.9 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Zoetis Inc. (NYSE:ZTS) reported its Actual EPS of $0.83/share. The analysts offering Earnings Estimates for the company were believing that Zoetis Inc. could bring EPS of $0.77/share. The difference between Actual EPS and Estimated EPS was 0.06 Percent. Thus showing an Earnings Surprise of 7.8 Percent.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
In the last trading session, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) added its value by -0.14% closing at the price of $13.8. The stock currently has market capitalization of 2.1 Billion, with average volume of 1.3 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is showing beta of 1.25. This particular value of beta suggests that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has historically moved 125% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is at $-1.67.
The stock currently has RSI of 51.81. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company’s first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) topped its 52-week high price of $21.20 on 07/13/18 and 52-Week Low Price of $11.02 on 11/15/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.93% and monthly volatility of 5.78% respectively.